David Hur, MD, director of structural heart disease/interventional imaging at the VA Connecticut Healthcare System, and an assistant professor of medicine at Yale, explains the technical challenges encountered in cardiac computed tomography (CT) and how to overcome them.

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

ACC President Hadley Wilson, MD, explains the big impact four late-breaking studies on intravascular imaging may have on revising PCI guidelines.

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Should interventional cardiologists be using X, the website formerly known as Twitter? A team of specialists explored that very question, sharing its assessment in JSCAI.

Eric Williamson, MD, a former SCCT president, examined recruitment and retention strategies for physicians and technologists in the field of cardiac CT. 

The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview.